Adaptimmune Therapeutics Management
Management criteria checks 3/4
Adaptimmune Therapeutics' CEO is Ad Rawcliffe, appointed in Sep 2019, has a tenure of 5.67 years. total yearly compensation is $2.11M, comprised of 32.1% salary and 67.9% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $115.64K. The average tenure of the management team and the board of directors is 5.4 years and 10.2 years respectively.
Key information
Ad Rawcliffe
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 32.1% |
| CEO tenure | 5.7yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.4yrs |
| Board average tenure | 10.2yrs |
Recent management updates
Recent updates
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Apr 04 Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Mar 11
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%
Jan 01Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Dec 15Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$2m | US$676k | -US$71m |
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$163m |
| Dec 31 2023 | US$3m | US$650k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$650k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$175m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$4m | US$617k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$140m |
| Dec 31 2020 | US$3m | US$574k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$123m |
| Jun 30 2020 | n/a | n/a | -US$127m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$2m | US$500k | -US$137m |
| Sep 30 2019 | n/a | n/a | -US$144m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$102m |
| Dec 31 2018 | US$1m | US$457k | -US$96m |
Compensation vs Market: Ad's total compensation ($USD2.11M) is above average for companies of similar size in the US market ($USD679.45K).
Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.
CEO
Ad Rawcliffe (52 yo)
5.7yrs
Tenure
US$2,109,075
Compensation
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.7yrs | US$2.11m | 0.15% $ 115.6k | |
| COO & Chief Compliance Officer | 8.2yrs | US$1.06m | 0.075% $ 58.2k | |
| Chief Commercial Officer | 1.2yrs | US$1.75m | 0.042% $ 32.5k | |
| Co-Founder | no data | US$1.18m | 0% $ 0 | |
| Chief Scientific Officer | 3yrs | no data | 0.0047% $ 3.6k | |
| VP of Corporate Affairs & Investor Relations | no data | no data | no data | |
| Senior VP & General Counsel | 9.6yrs | no data | no data | |
| Senior Director of Corporate Communications | no data | no data | no data | |
| Chief Patient Supply Officer | 5.8yrs | US$1.72m | 0.065% $ 50.0k | |
| Chief Medical Officer | 5.3yrs | US$1.18m | 0.050% $ 39.0k | |
| Senior Vice President of Late Stage Development | 5.4yrs | no data | no data | |
| Senior Vice President of Early-Stage Development | 1.7yrs | no data | no data |
5.4yrs
Average Tenure
55yo
Average Age
Experienced Management: ADAP's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.7yrs | US$2.11m | 0.15% $ 115.6k | |
| Independent Chairman of the Board of Directors | 10.3yrs | US$204.20k | 0% $ 0 | |
| Independent Non-Executive Director | 10.2yrs | US$156.57k | 0.0091% $ 7.0k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 6.8yrs | US$142.62k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 10.3yrs | US$152.09k | 0% $ 0 |
10.2yrs
Average Tenure
59.5yo
Average Age
Experienced Board: ADAP's board of directors are seasoned and experienced ( 10.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 16:42 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adaptimmune Therapeutics plc is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Ying Huang | BofA Global Research |
| Olga Smolentseva | Bryan Garnier & Co |